Ali Kaan Güren, Nazım Can Demircan, Özge Gümüşay, Eda Tanrıkulu Şimşek, Fatih Kemik, Çağla Karaoğlu, Taha Koray Şahin, Salih Tünbekici, Kübra Akkaya, Murad Guliyev, Barış Gezici, Hasibe Bilge Gür, Delyadil Karakaş, Ahmet Ünlü, Oğuz Altunok, İsmail Nazlı, Sedat Biter, Tuğba Kaya, Özge Yetginoğlu, Tuğçe Kübra Güneş, Lamia Şeker Can, Nargiz Majidova, Nadiye Sever, Aysun Fatma Akkuş, İsmail Oğuz Kara, Banu Öztürk, Adem Deligönül, Muhammet Ali Kaplan, Elif Atağ, İlhan Hacıbekiroğlu, Nebi Serkan Demirci, Fatih Selçuk Biricik, Deniz Can Güven, Sercan Aksoy, Rukiye Arıkan, Murat Sarı, İbrahim Vedat Bayoğlu, Osman Köstek
{"title":"免疫相关不良事件作为派姆单抗治疗早期三阴性乳腺癌病理完全缓解的预测因素","authors":"Ali Kaan Güren, Nazım Can Demircan, Özge Gümüşay, Eda Tanrıkulu Şimşek, Fatih Kemik, Çağla Karaoğlu, Taha Koray Şahin, Salih Tünbekici, Kübra Akkaya, Murad Guliyev, Barış Gezici, Hasibe Bilge Gür, Delyadil Karakaş, Ahmet Ünlü, Oğuz Altunok, İsmail Nazlı, Sedat Biter, Tuğba Kaya, Özge Yetginoğlu, Tuğçe Kübra Güneş, Lamia Şeker Can, Nargiz Majidova, Nadiye Sever, Aysun Fatma Akkuş, İsmail Oğuz Kara, Banu Öztürk, Adem Deligönül, Muhammet Ali Kaplan, Elif Atağ, İlhan Hacıbekiroğlu, Nebi Serkan Demirci, Fatih Selçuk Biricik, Deniz Can Güven, Sercan Aksoy, Rukiye Arıkan, Murat Sarı, İbrahim Vedat Bayoğlu, Osman Köstek","doi":"10.1080/1750743X.2026.2662201","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemoimmunotherapy improved pathological complete response (pCR) rates in early triple-negative breast cancer (TNBC). However, the relationship between immune-related adverse events (irAEs) and treatment response remains unclear. This study evaluated the association between the development of irAEs and pCR in TNBC patients receiving neoadjuvant pembrolizumab-based therapy.</p><p><strong>Method: </strong>In this multicenter retrospective study, early TNBC patients who received neoadjuvant pembrolizumab-based therapy were evaluated. Clinicopathologic features, irAE occurrence, and pCR rates were recorded and analyzed.</p><p><strong>Results: </strong>Among 203 patients who completed neoadjuvant treatment and underwent surgery, 127 (62.6%) achieved pCR. irAEs were more frequent in the pCR group compared with the non-pCR group (35.4% vs 19.7%, respectively; <i>p</i> = 0.01). Both univariate and multivariate analyses confirmed a significant association between irAE development and pCR.</p><p><strong>Conclusion: </strong>In patients with early TNBC treated with neoadjuvant pembrolizumab, irAEs occurred more often in those achieving pCR. These findings suggest that irAEs may reflect enhanced immune activation and could serve as a potential indicator of treatment response. Further prospective studies are needed to validate this observation and clarify its clinical relevance.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.3000,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.\",\"authors\":\"Ali Kaan Güren, Nazım Can Demircan, Özge Gümüşay, Eda Tanrıkulu Şimşek, Fatih Kemik, Çağla Karaoğlu, Taha Koray Şahin, Salih Tünbekici, Kübra Akkaya, Murad Guliyev, Barış Gezici, Hasibe Bilge Gür, Delyadil Karakaş, Ahmet Ünlü, Oğuz Altunok, İsmail Nazlı, Sedat Biter, Tuğba Kaya, Özge Yetginoğlu, Tuğçe Kübra Güneş, Lamia Şeker Can, Nargiz Majidova, Nadiye Sever, Aysun Fatma Akkuş, İsmail Oğuz Kara, Banu Öztürk, Adem Deligönül, Muhammet Ali Kaplan, Elif Atağ, İlhan Hacıbekiroğlu, Nebi Serkan Demirci, Fatih Selçuk Biricik, Deniz Can Güven, Sercan Aksoy, Rukiye Arıkan, Murat Sarı, İbrahim Vedat Bayoğlu, Osman Köstek\",\"doi\":\"10.1080/1750743X.2026.2662201\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Neoadjuvant chemoimmunotherapy improved pathological complete response (pCR) rates in early triple-negative breast cancer (TNBC). However, the relationship between immune-related adverse events (irAEs) and treatment response remains unclear. This study evaluated the association between the development of irAEs and pCR in TNBC patients receiving neoadjuvant pembrolizumab-based therapy.</p><p><strong>Method: </strong>In this multicenter retrospective study, early TNBC patients who received neoadjuvant pembrolizumab-based therapy were evaluated. Clinicopathologic features, irAE occurrence, and pCR rates were recorded and analyzed.</p><p><strong>Results: </strong>Among 203 patients who completed neoadjuvant treatment and underwent surgery, 127 (62.6%) achieved pCR. irAEs were more frequent in the pCR group compared with the non-pCR group (35.4% vs 19.7%, respectively; <i>p</i> = 0.01). Both univariate and multivariate analyses confirmed a significant association between irAE development and pCR.</p><p><strong>Conclusion: </strong>In patients with early TNBC treated with neoadjuvant pembrolizumab, irAEs occurred more often in those achieving pCR. These findings suggest that irAEs may reflect enhanced immune activation and could serve as a potential indicator of treatment response. Further prospective studies are needed to validate this observation and clarify its clinical relevance.</p>\",\"PeriodicalId\":13328,\"journal\":{\"name\":\"Immunotherapy\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2026-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1750743X.2026.2662201\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2026.2662201","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.
Purpose: Neoadjuvant chemoimmunotherapy improved pathological complete response (pCR) rates in early triple-negative breast cancer (TNBC). However, the relationship between immune-related adverse events (irAEs) and treatment response remains unclear. This study evaluated the association between the development of irAEs and pCR in TNBC patients receiving neoadjuvant pembrolizumab-based therapy.
Method: In this multicenter retrospective study, early TNBC patients who received neoadjuvant pembrolizumab-based therapy were evaluated. Clinicopathologic features, irAE occurrence, and pCR rates were recorded and analyzed.
Results: Among 203 patients who completed neoadjuvant treatment and underwent surgery, 127 (62.6%) achieved pCR. irAEs were more frequent in the pCR group compared with the non-pCR group (35.4% vs 19.7%, respectively; p = 0.01). Both univariate and multivariate analyses confirmed a significant association between irAE development and pCR.
Conclusion: In patients with early TNBC treated with neoadjuvant pembrolizumab, irAEs occurred more often in those achieving pCR. These findings suggest that irAEs may reflect enhanced immune activation and could serve as a potential indicator of treatment response. Further prospective studies are needed to validate this observation and clarify its clinical relevance.
期刊介绍：
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
